- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06199713
Korelacja wczesnego FDG PET/CT i ctDNA u pacjentów z czerniakiem leczonych inhibitorem immunologicznego punktu kontrolnego (ICI)
Korelacja między wczesną tomografią emisyjną/tomografią komputerową z pozytronem 18F-fluorodeoksyglukozy (PET/CT) a DNA nowotworu krążącego (ctDNA) u pacjentów z zaawansowanym czerniakiem leczonych inhibitorami immunologicznego punktu kontrolnego
The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
This is a pilot, prospective, observational study to estimate the degree to which baseline and early interval 18F-FDG PET/CT imaging within 3-4 weeks of ICI therapy initiation can accurately correlate with ctDNA level trends, predict clinical response, onset of immune-related adverse events, and survival outcomes in advanced stage melanoma patients.
Primary Objective
• To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks correlates with ctDNA level changes in advanced melanoma patients.
Secondary Objectives
- To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks predicts clinical efficacy at standard disease assessment time points in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT predicts development of clinical irAEs in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts progression-free survival (PFS) in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts overall survival (OS) in advanced melanoma patients.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Wisconsin
-
Madison, Wisconsin, Stany Zjednoczone, 53792
- University of Wisconsin Hospitals and Clinics (UWHC)
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
24 participants with advanced stage III or stage IV melanoma with measurable disease who are deemed appropriate for treatment with ICI therapy.
Opis
Inclusion Criteria:
- Willing to provide informed consent.
- Must have an advanced stage III or stage IV melanoma diagnosis for which treatment with ipilimumab, nivolumab, and/or pembrolizumab, either alone or in combination with other ICI therapy, is planned.
- Must be planning to participate in Signatera™ (ctDNA level) monitoring with standard of care laboratory testing routinely obtained for treatment with ICI therapy.
- Individuals at least 18 years of age.
- Women of childbearing potential must be willing to use effective contraception as discussed with their oncologist while participating in this study.
- Willing to comply with all study procedures and be available for the duration of the study.
Exclusion Criteria:
- Not able to receive treatment with ICI therapy
- Use of investigational drugs, biologics, or devices within 30 days prior to enrollment.
- Women who are pregnant, lactating, or planning on becoming pregnant during the study.
- Not suitable for study participation due to other reasons at the discretion of the investigators.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
Pacjenci z zaawansowanym czerniakiem z inhibitorami punktów kontrolnych układu odpornościowego
|
research scan 3-4 weeks after start of immunotherapy
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in ctDNA level from baseline to 3-4 week after the start of therapy
Ramy czasowe: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
ctDNA level is monitored per standard of care in this population, data from chart review. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Change in 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
Ramy czasowe: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy reported as SUV max. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Correlation between ctDNA level change and 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
Ramy czasowe: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy with quantitative changes in ctDNA levels at baseline and at 3-4 weeks after starting ICI therapy. Pearson's or Rank's correlation coefficient will be used to measure the baseline measures for ctDNA level trends and PET/CT responses and for those measurements at 3-4 weeks. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Diagnostic Accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition as measured by Area under the Curve
Ramy czasowe: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Receiver-operator curve analysis will be performed to determine the diagnostic accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition (area under the curve). |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Objective Response Rate (ORR)
Ramy czasowe: up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. ORR is Partial Response (PR) plus Complete Response (CR). |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Disease Control Rate (DCR)
Ramy czasowe: up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. DCR is Stable Disease (SD) plus PR plus CR. |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Change in Standard Uptake Value (SUV) metrics with onset of Immune Related Adverse Events (irAE)
Ramy czasowe: up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate organ-level FDG uptake and changes from the baseline and early 18F-FDG PET/CT assessment with onset of first, second, and third symptomatic irAE per CTCAE v5.0 |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Progression Free Survival (PFS)
Ramy czasowe: up to 3 years after the first ICI dose (approximately 3 years on study)
|
PFS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and PFS
Ramy czasowe: up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early 18F-FDG PET/CT treatment response with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and PFS
Ramy czasowe: up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early ctDNA level trends with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Overall Survival (OS)
Ramy czasowe: up to 3 years after the first ICI dose (approximately 3 years on study)
|
OS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and OS
Ramy czasowe: up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early 18F-FDG PET/CT response assessment with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and OS
Ramy czasowe: up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early ctDNA level trends with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Vincent Ma, MD, University of Wisconsin, Madison
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Nowotwory według lokalizacji
- Nowotwory
- Nowotwory według typu histologicznego
- Choroby skórne
- Nowotwory neuroektodermalne
- Nowotwory, komórki rozrodcze i embrionalne
- Nowotwory, tkanka nerwowa
- Guzy neuroendokrynne
- Nevi i czerniaki
- Nowotwory skóry
- Choroby skóry i tkanki łącznej
- Czerniak
- Techniki i procedury diagnostyczne
- Diagnoza
- Tomografia
- Obrazowanie diagnostyczne
- Radiografia
- Interpretacja obrazu, wspomagana komputerowo
- Ulepszenie obrazu radiograficznego
- Ulepszenie obrazu
- Fotografia
- Tomografia, rentgen
- Tomografia, obliczona promieniowanie rentgenowskie
Inne numery identyfikacyjne badania
- 2023-1089
- A534260 (Inny identyfikator: UW Madison)
- UW23077 (Inny identyfikator: UWCCC)
- Protocol Version 2/12/2024 (Inny identyfikator: UW Madison)
- NCI-2023-11059 (Identyfikator rejestru: NCI Trial ID)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .